EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis

Matin Ghanavati, Yasaman Khorshidi, Mahdi Shadnoush, Mohammad Esmaeil Akbari iD, Seyed Hossein Ardehali, Yanin Chavarri-Guerra, Atieh Akbari, Regina Barragan-Carrillo, Manoochehr Amin Amlashi, Zeinab Javid, Jamal Rahmani iD

Cancer Reports · 2023-04 · 6 (4)

DOI: 10.1002/cnr2.1806 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Reports, online erschienen am 14.03.2023. Verfasst von Matin Ghanavati und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Nutrition & Dietetics, Faculty of Nutrition Science and Food Technology, National Nutrition and Food Technology Research Insti…. Hauptthemen laut MEDLINE: Breast Neoplasms, Endometrial Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Worse prognosis of endometrial cancers (EC) in tamoxifen‐treated women compared to non‐tamoxifen‐treated women been proposed. The relationship between tamoxifen treatment of breast cancer (BC) and the risk of EC is controversial and there is no agreement between publication results on this issue (the answer to all comments provided in the page 2 of manuscript). The aim of this study is investigation the association between tamoxifen treatment and the risk of EC in patients with BC. Methods and Results We conducted a comprehensive search with related keywords in MEDLINE/PubMed, SCOPUS, and Web of Science databases until April 16, 2022. Random‐effects model (DerSimonian and Laird) was used to pool risk ratios (RRs) with 95% confidence intervals (CIs) of EC. Dose, cumulative dose, and duration‐response analysis were performed in linear and non‐linear states. Twenty‐six studies reported a relation between tamoxifen treatment and risk of EC in patients with BC. Results showed a direct relationship between tamoxifen use and EC (RR: 2.03, 95% CI: 1.68–2.45; I2:76%). By increase the age of participants, the risk of EC was decrease (coef = −.0206), although this was not statistically significant ( p = .37). Linear dose–response model indicated a direct significant association between dose and duration use of tamoxifen and EC (dose: exe( b ) = 1.019, p = .001; duration: exe( b ) = 1.014, p = .001). Non‐linear dose–response analysis confirmed linear analysis.

Conclusion

This study highlights that tamoxifen use is a significant risk factor related to the incidence of EC in patients with BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsEndometrial NeoplasmsFemaleHumansPrognosisRisk FactorsTamoxifen

Stichwörter der Autor:innen

breast cancerdose-responseendometrial cancertamoxifen

Substanzen

Tamoxifen

Autor:innen und Institutionen

  • Department of Clinical Nutrition & Dietetics, Faculty of Nutrition Science and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Anesthesiology and Critical Care, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
  • Department of Nutrition, Farhikhtegan hospital, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

ORCID-Profile: Mohammad Esmaeil Akbari, Jamal Rahmani

Zitieren

APA

Ghanavati, M., Khorshidi, Y., Shadnoush, M., Akbari, M. E., Ardehali, S. H., Chavarri-Guerra, Y., Akbari, A., Barragan-Carrillo, R., Amin Amlashi, M., Javid, Z., & Rahmani, J. (2023). Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis. Cancer Reports, 6(4). https://doi.org/10.1002/cnr2.1806

Vancouver

Ghanavati M, Khorshidi Y, Shadnoush M, Akbari ME, Ardehali SH, Chavarri-Guerra Y, et al. Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis. Cancer Reports. 2023;6(4). doi:10.1002/cnr2.1806

BibTeX
@article{Ghanavati2023,
  author = {Ghanavati, Matin and Khorshidi, Yasaman and Shadnoush, Mahdi and Akbari, Mohammad Esmaeil and Ardehali, Seyed Hossein and Chavarri-Guerra, Yanin and Akbari, Atieh and Barragan-Carrillo, Regina and Amin Amlashi, Manoochehr and Javid, Zeinab and Rahmani, Jamal},
  title = {Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis},
  journal = {Cancer Reports},
  year = {2023},
  volume = {6},
  number = {4},
  doi = {10.1002/cnr2.1806}
}
Kostenlos starten →